To Determine if Olanzapine is More Cost Effective Than Haloperidol for the Treatment of Schizophrenia

Completed · Phase 4

Conditions studied: Schizoaffective Disorder, Schizophrenia

In brief

Although currently marketed antipsychotic drugs are useful in the treatment of schizophrenia, efficacy and safety profiles need to be improved. Forty to eighty percent of patients either fail to respond or only partially respond to conventional antipsychotic agents. Secondary symptoms may be unimproved even in patients who respond to treatment. A variety of adverse events occur in patients receiving currently available agents. The severity of these events contributes to the poor compliance that is observed in this patient population. Olanzapine is a novel antipsychotic agent with a reduced incidence of extrapyramidal symptoms. Other side effects are minimal.

Key facts

Study ID
NCT00007774
Run by
US Department of Veterans Affairs
People needed
600
Starts
1998-03-01
Last updated by the study team
2009-02-04

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.